GSK's Phase 3 Trial In Adults 50 Years And Older Of Arexvy (Respiratory Syncytial Virus Vaccine) When Co-administered With Shingrix (Zoster Vaccine) Met Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
GSK's Phase 3 trial of Arexvy, an RSV vaccine, co-administered with Shingrix, a shingles vaccine, met its primary endpoint in adults 50 and older. The vaccines were well tolerated, showing acceptable safety profiles, advancing the science of co-administration of adult vaccines.
September 18, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's successful Phase 3 trial of Arexvy and Shingrix vaccines in adults 50+ shows promising results for co-administration, potentially boosting GSK's vaccine portfolio and market position.
The successful trial results for Arexvy and Shingrix in co-administration could enhance GSK's market position in the vaccine sector, potentially leading to increased sales and market share. The positive safety and efficacy data are likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100